(BPT) - Talking about and acknowledging mental health challenges have evolved, with more acceptance and mainstream conversation in recent years from both patients and their loved ones, as well as
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec for the treatment of X-linked retinitis.
Modern Schizophrenia Treatment Plans Should Include Less-Frequent Dosing Options for Adult Patients dailypost.vu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypost.vu Daily Mail and Mail on Sunday newspapers.
Heart to Heart With a Leading Cardiologist: What You Need to Know About Coronary Artery Disease yankton.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yankton.net Daily Mail and Mail on Sunday newspapers.
MeiraGTx (NASDAQ:MGTX – Get Free Report) and Alvotech (NYSE:ALVO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation. Institutional and Insider Ownership 64.8% of MeiraGTx shares are […]